Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harmony Study of ADP101 in Food Allergy
NCT04856865Phase 2Completed
- Sponsor
- Alladapt Immunotherapeutics
- Start
- Apr 2021
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes, Allergy Immunotherapy
- Countries
- 1
01
Overview
A Phase 2 trial of ADP101 in food allergy, sponsored by Alladapt Immunotherapeutics. Started Apr 2021; status: completed.
02
Drugs
ADP101
03
Conditions
food allergy
Beyond the preview
Go deeper on NCT04856865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856865.